

PAUL A. ARISTOFF

Aristoff Consulting LLC
8265 Trail Ridge
Dexter, MI 48130

734-945-7413
aristoff@charter.net

CAREER SUMMARY

A drug discovery scientist and leader with extensive experience in the pharmaceutical industry leading multi-disciplinary research teams and chemistry departments of up to 160 scientists in a broad variety of therapeutic areas that produced over 35 development candidates, including three drugs that are on the US market. Inventor or co-inventor on twelve development candidates, including four drugs that reached the marketplace. Successfully initiated and led multiple collaborations with academia and the biotech industry. Excellent interpersonal and communication skills. Broad medicinal chemistry expertise, particularly in the antibacterial, antiviral, and oncology research areas.

PROFESSIONAL EXPERIENCE

ARISTOFF CONSULTING LLC

2008 –

President and Founder

Provide medicinal chemistry consulting services to clients in industry, academia and government.

PFIZER, INC., ANN ARBOR, MI

2003 - 2008

Senior Director, Antibacterial Chemistry

Provided overall leadership to 33 medicinal chemists hiring seven in 2005 in the Antibacterial Chemistry group in Ann Arbor.

- Led a group charged with designing and synthesizing antibacterial compounds to treat serious hospital and community infections delivering six development candidates in four years.
- Chaired a joint research committee leading the Vicuron Pharmaceuticals / Pfizer collaboration on Oxazolidinones, resulting in the delivery of four development candidates and a relationship that helped enable the purchase of Vicuron which increased the revenue potential for Pfizer by the acquisition of two Vicuron late stage clinical candidates (dalbavancin and Eraxis™)

PHARMACIA, KALAMAZOO, MI

1978 – 2003

Senior Director, Chemistry

1999-2003

Provided leadership of the Infectious Diseases Discovery Portfolio that produced six development candidates.

- Served as overall project leader of the Oxazolidinone Team and chair of the Pharmacia / Vicuron Collaboration (formerly Versicor, Inc.) resulting in the discovery of three development candidates.
- Managed the hiring of 50 medicinal chemists (including 20 PhD chemists) identifying their skills and enabling the continuation of discovery projects.

Director, Medicinal Chemistry, Pharmacia & Upjohn

1995 -1999

Provided chemistry leadership for 160 scientists in the Kalamazoo Chemistry Department including the medicinal, analytical, and the structural chemistry groups, enabling the delivery of 15 development candidates, including clinical candidates from the antibacterial, antiviral, CNS, cardiovascular, diabetes and inflammation disease areas.

- Led the Oxazolidinone Program Team and the Versicor Collaboration on Oxazolidinones, resulting in the delivery of four antibacterial development candidates.
- Led the global collaboration for Pharmacia & Upjohn with the Axys Company (formerly Arris, Inc.) on combinatorial chemistry in order to train company scientists on these chemistry techniques and to enlarge the P & U chemical screening file.

Director, Medicinal Chemistry Research, The Upjohn Company 1991-1995

Served as the overall head of medicinal chemistry, leading the 100 medicinal chemists responsible for all discovery chemistry projects at Upjohn, resulting in the discovery of 16 development candidates in the antibacterial, antiviral, CNS, and inflammatory diseases areas.

- One development candidate discovered by scientists reporting to me, linezolid (Zyvox[®]) for the treatment of serious gram-positive infections, represented the first new class of antibacterial agents approved in over 35 years by the FDA when it entered the marketplace in 2000. Annual sales exceed the one billion dollar mark, and the discovery has been recognized by national awards from both PhRMA and the American Chemical Society.
- Another development candidate, tipranavir (Aptivus[®]), designed and synthesized in my own laboratory as a non-peptidic HIV protease inhibitor, entered the US marketplace in 2005.

Associate Director, Cancer and Viral Diseases Research, The Upjohn Company 1984-1990

Served as overall Chemistry head directing operations and managing a staff of 20 chemists.

- Led the CC-1065 Analog Project, producing the clinical candidates adozelesin, bizelesin (developed via an NCI collaboration), and carzelesin (developed via an EORTC collaboration).
- Served as chemistry lead on an NIH AIDS grant directed towards the discovery of non-nucleoside HIV reverse transcriptase inhibitors, enabling the discovery of clinical candidate atevirdine.
- Served as Project Leader of the HIV Non-nucleoside Reverse Transcriptase Inhibitor Project that discovered atevirdine and delavirdine (Rescriptor[®]), the latter reaching the US marketplace in 1997.
- Served as chemistry leader on an angiogenesis collaboration with Professor Judah Folkman at Harvard which ultimately led to being co-inventor on anecortave acetate (Retaane[™]) that has been used for the treatment of ocular disease.

Scientist, Experimental Chemistry Research, The Upjohn Company 1978-1984

Served as laboratory lead scientist charged with the discovery of stable prostacyclin analogs.

- Designed and synthesized ciprostone calcium, which reached phase III clinical evaluation.
- Designed and synthesized treprostinil sodium (Remodulin[®]), which is indicated for the treatment of severe pulmonary arterial hypertension (PAH) and reached the US marketplace in 2002.

EDUCATION

Postdoctoral Research Fellow in Organic Chemistry with A. Eschenmoser Swiss Federal Institute of Technology (ETH), Zürich, Switzerland	1977-1978
Ph.D. , Organic Chemistry, California Institute of Technology, Pasadena, California Thesis Advisor: R.E. Ireland	1973-1977
B.A. / M.S. (Combined) in Chemistry, Northwestern University, Evanston, Illinois Thesis Advisor: J.A. Marshall	1969-1973

ACADEMIC AND PROFESSIONAL HONORS

Visiting Research Scientist, Med. Chem. Dept., University of Michigan	2008 -
Editorial Advisory Board member for <i>Chemical Biology & Drug Design</i>	2006 -
Upjohn Achievement in Science and Medicine Award	1995
W. E. Upjohn Award	1991
Member of Ad Hoc Task Force to Monitor <i>JACS</i>	1989 - 1990
Editorial Advisory Board Member for <i>Journal of Organic Chemistry</i>	1988 - 1992
NSF National Needs Postdoctoral Fellowship	1977 - 1978
National Science Foundation Graduate Fellowship	1973 - 1976
American Institute of Chemists Student Award	1973
Phi Beta Kappa; B.A. with Distinction and Departmental Honors	1973

PUBLICATIONS, PRESENTATIONS, AND PATENTS

Author or co-author on 58 publications and 82 presentations (including 40 invited lectures).
Inventor or co-inventor on 30 issued US patents, including for four marketed drugs.

PUBLICATIONS

1. R.E. Ireland, P.A. Aristoff, and C.F. Hoyng. "Experiments Directed toward the Total Synthesis of Terpenes. 23. Synthesis of 4a-Methyl-4,4a,7,8-tetrahydro-9H-benzocycloheptene-2(3H),5(6H)-dione (B-Homo Wieland-Miescher Ketone): A Versatile Intermediate for Terpene Synthesis." *J Org Chem* **44**, 4318 (1979).
2. R.E. Ireland and P.A. Aristoff. "Experiments Directed toward the Total Synthesis of Terpenes. 24. On the π Route to Aphidicolin: Synthesis of 18,19-Bisnoraphidicolan-3-one." *J Org Chem* **44**, 4323 (1979).
3. P.A. Aristoff. "Practical Synthesis of 6a-Carbaprostaglandin I₂ ." *J Org Chem* **46**, 1954 (1981).
4. P.A. Aristoff and A. W. Harrison. "Synthesis of Benzindene Prostaglandins: A Novel Potent Class of Stable Prostacyclin Analogs." *Tetrahedron Lett* **23**, 2067 (1982).
5. P.A. Aristoff, A.W. Harrison, J.W. Aiken, R.R. Gorman, and J.E. Pike. "Synthesis and Structure-Activity Relationship of Novel Stable Prostacyclin Analogs." *In Advances in Prostaglandin, Thromboxane, and Leukotriene Research*, Vol. 11, ed. by B. Samuelsson, R. Paoletti, and P. Ramwell, 267-274, Raven Press, New York, 1983.
6. P.A. Aristoff. "Use of Crown Ether in the Intramolecular Wadsworth-Emmons Reaction. Synthesis of Bicyclo[3.3.0]oct-1-en-3-one." *Synth Commun* **13**, 145 (1983).
7. P.A. Aristoff and C.L. Nelson. "Practical Synthesis of 3,3,4,4-Tetramethylcyclopentanone." *Org Prep Proc Int* **15**, 149 (1983).
8. P.A. Aristoff, P.D. Johnson and A.W. Harrison. "Synthesis of 9-Substituted Carbacyclin Analogues." *J Org Chem* **48**, 5341 (1983).
9. P.A. Aristoff, A.W. Harrison and A.W. Huber. "Synthesis of Benzopyran Prostaglandins, Potent Stable Prostacyclin Analogs, via an Intramolecular Mitsunobu Reaction." *Tetrahedron Lett* **24**, 3955 (1984).
10. O. Radmark, C. Serhan, M. Hamberg, U. Lundberg, M.D. Ennis, G.L. Bundy, T.D. Oglesby, P.A. Aristoff, A.W. Harrison, G. Slomp, T.A. Scahill, G. Weissmann, B. Samuelsson. "Stereochemistry, Total Synthesis and Biological Activity of 14,15-Dihydroxy-5,8,10,12-eicosatetraenoic Acid." *J Biol Chem* **259**, 13011 (1984).
11. P.A. Aristoff. "The Synthesis of Prostacyclin Analogues." *In Advances in Prostaglandin, Thromboxane, and Leukotriene Research*, Vol. 14, ed. by J.E. Pike and D.R. Morton, 309-392, Raven Press, New York, 1985.
12. P.A. Aristoff. "Improved Method for the Conversion of Enol Lactones to Cyclic α,β -Unsaturated Ketones." *J Org Chem* **50**, 1765 (1985).
13. P.A. Aristoff, A.W. Harrison, P.D. Johnson, and A. Robert. "Synthesis and Structure-Activity Relationships of Benzindene Prostaglandins: Novel Potent Antiulcer Agents." *In Advances in Prostaglandin, Thromboxane, and Leukotriene Research*. Vol. 15, ed. by O. Hayaishi and S. Yamamoto, 275-277, Raven Press, New York, 1985.

14. A. Robert, P.A. Aristoff, M.G. Wendling, F.A. Kimball, W.L. Miller, Jr., and R.R. Gorman. "Gastrointestinal Properties of U-68,215, a Stable Prostacyclin Analog." In *Advances in Prostaglandin, Thromboxane, and Leukotriene Research*. Vol. 15, ed. by O. Hayaishi and S. Yamamoto, 641-644, Raven Press, New York, 1985.
15. A. Robert, P.A. Aristoff, M.G. Wendling, F.A. Kimball, W.L. Miller, Jr., and R.R. Gorman. "Cytoprotective and Antisecretory Properties of a Non-Diarrheogenic and Non-Uterotonic Prostacyclin Analog: U-68,215." *Prostaglandins*, **30**, 619 (1985).
16. A. Robert, P.A. Aristoff, M.G. Wendling, F.A. Kimball, W.L. Miller, Jr., and R.R. Gorman. "Cytoprotective and Antisecretory Properties of a Non-Diarrheogenic and Non-Uterotonic Prostacyclin Analog: U-68,215." *Gastroenterology* **88**, 1556 (1985).
17. P.A. Aristoff, P.D. Johnson, and A.W. Harrison. "Total Synthesis of a Novel Antiulcer Agent via a Modification of the Intramolecular Wadsworth-Emmons-Wittig Reaction." *J Am Chem Soc* **107**, 7967 (1985).
18. P.A. Aristoff. "Ciprostene Calcium." *Drugs of the Future* **10**, 900 (1985).
19. E. Vogel, G. Caravatti, P. Franck, P.A. Aristoff, C. Moody, A-M. Becker, D. Felix, and A. Eschenmoser. "On the Stereochemistry of E' and E"-Reactions." *Chem. Lett* **219** (1987).
20. R.C. Kelly, I. Gebhard, N. Wicnienski, P.A. Aristoff, P.D. Johnson, and D.G. Martin. "Coupling of Cyclopropapyrroloindole (CPI) Derivatives. The Preparation of CC-1065, ent-CC-1065, and Analogs". *J Am Chem Soc* **109**, 6837 (1987).
21. C.H. Lin, P.A. Aristoff, P.D. Johnson, J.P. McGrath, J.M. Timko, and A. Robert. "Benzindene Prostaglandins. Synthesis of Optically Pure 15-Deoxy-U-68,215 and its Enantiomer via a Modified Intramolecular Wadsworth-Emmons-Wittig Reaction." *J Org Chem* **52**, 5594 (1987).
22. L.H. Hurley, C.S. Lee, J.P. McGovren, M.A. Warpehoski, M.A. Mitchell, R.C. Kelly, and P.A. Aristoff. "Molecular Basis for Sequence-Specific DNA Alkylation by CC-1065." *Biochemistry* **27**, 3886 (1988).
23. L.H. Hurley, C.S. Lee, J.P. McGovren, M.A. Warpehoski, M.A. Mitchell, R.C. Kelly, and P.A. Aristoff. "Reaction of CC-1065 and Select Synthetic Analogs with DNA." *Biochemical Pharmacol* **37**, 1795 (1988).
24. J.F. Fisher and P.A. Aristoff. "The Chemistry of DNA Modification by Antitumor Antibiotics." In *Progress in Drug Research*, Vol. 32, ed. by E. Jucker, 411-498, Birkhauser Verlag, Basel, 1988.
25. M.A. Mitchell, P.D. Johnson, M.G. Williams, and P.A. Aristoff. "Interstrand DNA Crosslinking with Dimers of the Spirocyclopropyl Alkylating Moiety of CC-1065." *J Am Chem Soc* **111**, 6428 (1989).
26. P.D., Johnson and P.A. Aristoff. "General Procedure for the Synthesis of o-Amino phenylacetates by a Modification of the Gassman Reaction." *J Org Chem* **55**, 1374 (1990).
27. B.C. Moy, G.L. Petzold, G.J. Badiner, R.C. Kelly, P.A. Aristoff, E.G. Adams, L.H. Li and B.K. Bhuyan. "Characterization of B16 Melanoma Cells Resistant to the CC-1065 Analog, U-71,184." *Cancer Research* **50**, 2485 (1990).
28. D.L. Romero, M. Busso, C.-K. Tan, F. Reusser, J.R. Palmer, S.M. Poppe, P.A. Aristoff, K.M. Downey, A.G. So, L. Resnick and W.G. Tarpley. "Nonnucleoside Reverse Transcriptase Inhibitors that Potently and Specifically Block Human Immunodeficiency Virus Type 1 Replication." *Proc Natl Acad Sci* **88**, 8806 (1991).

29. P.A. Aristoff. "CC-1065 Analogs: Sequence Specific DNA-alkylating Antitumor Agents." In *Advances in Medicinal Chemistry*, Vol 2, ed. B. E. Maryanoff and C. A. Maryanoff, 67-110, JAI Press, Inc., Greenwich, CN, 1993.
30. K.A. Parker, C.A. Coburn, P.D. Johnson and P.A. Aristoff. Reductive Aromatization of Quinolns. "New Convenient Methods for the Regiospecific Synthesis of *p*-Hydroxy C-aryl Glycols." *J Org Chem* **57**, 5547 (1992).
31. P.A. Aristoff and P.D. Johnson. "Synthesis of CBI-PDE-I-Dimer, The Benzannelated Analogue of CC-1065." *J Org Chem* **57**, 6234 (1992).
32. I.W. Althaus, R.J. LeMay, A.J. Gonzales, M.R. Deibel, S.K. Sharma, F.J. Kezdy, L. Resnick, M.E. Busso, P.A. Aristoff and F. Reusser. "Enzymatic Kinetic Studies with the Non-nucleoside HIV Reverse Transcriptase Inhibitor U-9853." *Experientia* **48**, 1127 (1992).
33. P.A. Aristoff and J.P. McGovren. "Antitumor Agents Based on CC-1065." *Drug News & Perspectives* **6**, 229 (1993).
34. I.W. Althaus, J.J. Chou, A.J. Gonzales, M.R. Deibel, K.C. Chou, F.J. Kezdy, D.L. Romero, P.A. Aristoff, W.G. Tarpley and F. Reusser. "Steady-state Kinetic Studies with the Non-nucleoside HIV-1 Reverse Transcriptase Inhibitor U-87201E." *J Biol Chem* **268**, 6119 (1993).
35. T.J. Dueweke, S.M. Poppe, D.L. Romero, S.M. Swaney, A.G. So, K.M. Downey, I.W. Althaus, F. Reusser, L. Resnick, D. Mayers, P.A. Aristoff, R.C. Thomas and W.G. Tarpley. "U-90152, A Potent Inhibitor of Human Immunodeficiency Virus Type 1 Replication." *Antimicrobial Agents and Chemotherapy* **37**, 1127 (1993).
36. I.W. Althaus, A.J. Gonzales, J.J. Chou, D.C. Romero, M.R. Deibel, K.C. Chou, F.J. Kezdy, L. Resnick, M.E. Busso, A.G. So, K.M. Downey, R.C. Thomas, P.A. Aristoff, W.G. Tarpley and F. Reusser. "The Quinoline U-78036 is a Potent Inhibitor of HIV-1 Reverse Transcriptase." *J Biol Chem* **268**, 14875 (1993).
37. I.W. Althaus, J.J. Chou, A.J. Gonzales, M.R. Deibel, K.C. Chou, F.J. Kezdy, D.C. Romero, J.R. Palmer, R.C. Thomas, P.A. Aristoff, W.G. Tarpley and F. Reusser. "Kinetic Studies with the Non-nucleoside HIV-1 Reverse Transcriptase Inhibitor U-88204E." *Biochemistry* **32**, 6548 (1993).
38. P.A. Aristoff, P.D. Johnson, D. Sun and L.H. Hurley. "Synthesis and Biochemical Evaluation of CBI-PDE-I-Dimer, a Benzannelated Analog of (+)-CC-1065 that also Produces Delayed Lethality in Mice." *J Med Chem* **36**, 1956 (1993).
39. M.A. Mitchell, K.L. Wieland, P.A. Aristoff, P.D. Johnson and T.P. Dooley. "Sequence Selective Guanine Reactivity by Duocarmycin A." *Chem Res Toxicol* **6**, 421 (1993).
40. I.W. Althaus, J.J. Chou, A.J. Gonzales, R.J. LeMay, M.R. Deibel, K.C. Chou, F.J. Kezdy, D.L. Romero, R.C. Thomas, P.A. Aristoff, W.G. Tarpley and F. Reusser. "Steady-state Kinetic Studies with the Polysulfonate U-9843, an HIV Reverse Transcriptase Inhibitor." *Experientia* **50**, 23 (1993).
41. D.L. Romero, R.A. Morge, C. Biles, N. Berrios-Pena, P.D. May, J.R. Palmer, P.D. Johnson, H.W. Smith, M. Busso, C-K. Tan, R.L. Voorman, F. Reusser, I.W. Althaus, K.M. Downey, A.G. So, L. Resnick, W.G. Tarpley, and P.A. Aristoff. "Discovery, Synthesis, and Bioactivity of Bis(heteroaryl)piperazines. 1. A Novel Class of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors." *J Med Chem* **37**, 999 (1994).
42. I.W. Althaus, J.J. Chou, A.J. Gonzales, M.R. Deibel, K.C. Chou, F.J.Kezdy, D.C. Romero, R.C. Thomas, P.A. Aristoff, W.G. Tarpley and F. Reusser. "Kinetic Studies with the Non-nucleoside HIV-1 Reverse Transcriptase Inhibitor U-90152E." *Biochemical Pharmacol* **47**, 2017 (1994).

43. P.D. Johnson and P.A. Aristoff. "Methyl (Z)- (2)-(Bromomethyl)-2-butenonate." In *Encyclopedia of Reagents for Organic Synthesis*, Vol. 5, ed. by L.A. Paquette, 3445, John Wiley & Sons, Inc., Chichester, England, 1995.
44. I. Abraham, C.L. Wolf, K.E. Sampson, A.L. Laborde, J.A. Shelly, P.A. Aristoff, and H.I. Skulnick. "K252a, KT5720, KT5926, and U-98017 Support Taxol Dependent Cells and Synergize with Taxol." *Cancer Research* **54**, 5889 (1994).
45. P.A. Aristoff. "BHAPs, A Promising Class of Non-nucleoside HIV Reverse Transcriptase Inhibitors." *Drug News & Perspectives* **8**, 151 (1995).
46. I.W. Althaus, K.C. Chou, R.J. Lemay, K.M. Franks, M.R. Deibel, F.J. Kezdy, L. Resnick, M.E. Busso, A.G. So, K.M. Downey, D.L. Romero, R.C. Thomas, P.A. Aristoff, W.G. Tarpley, and F. Reusser. "The Benzylthio-pyrimidine U-31355 is a Potent Inhibitor of HIV-1 Reverse Transcriptase." *Biochemical Pharmacol* **8**, 743 (1996).
47. P.A. Aristoff. "Enzyme Inhibitors for the Treatment of AIDS." In *Medicinal Chemistry: Today and Tomorrow*, ed. by M. Yamazaki, 57 - 62, Blackwell Science Ltd, Oxford, 1997.
48. H.I. Skulnick, P.D. Johnson, W.J. Howe, P.K. Tomich, K.T. Chong, K.D. Watenpaugh, M.N. Janakiraman, L.A. Dolak, J.P. McGrath, J.C. Lynn, M.M. Horng, R.R. Hinshaw, G.L. Zipp, M.J. Ruwart, F.J. Schwende, W.Z. Zhong, G.E. Padbury, R.J. Dalga, L. Shiou, P.L. Possert, B.D. Rush, K.F. Wilkinson, G.M. Howard, L.N. Toth, M.G. Williams, T.J. Kakuk, S.L. Cole, R.M. Zaya, K.D. Lovasz, J.K. Morris, K.R. Romines, S. Thaisrivongs, and P.A. Aristoff. "Structure-Based Design of Sulfonamide Substituted Non-peptidic HIV Protease Inhibitors." *J Med Chem* **38**, 4968 (1995).
49. S. Thaisrivongs, D.L. Romero, R.A. Tommasi, M.N. Janakiraman, J.W. Strohbach, S.R. Turner, C. Biles, R.A. Morge, P.D. Johnson, P.A. Aristoff, P.K. Tomich, J.C. Lynn, M.-M. Horng, K.T. Chong, R.R. Hinshaw, W.J. Howe, B.C. Finzel, and K.D. Watenpaugh. "Structure-Based Design of HIV Protease Inhibitors: 5,6-Dihydro-4-hydroxy-2-pyrones as Effective, Non-peptidic Inhibitors." *J Med Chem.* **39**, 4630 (1996).
50. H.I. Skulnick, P.D. Johnson, P.A. Aristoff, J.K. Morris, K.D. Lovasz, W.J. Howe, K.D. Watenpaugh, M.N. Janakiraman, D.J. Anderson, R.J. Reischer, G.L. Bundy, T.M. Schwartz, L.S. Banitt, P.K. Tomich, J.C. Lynn, M.-M. Horng, K.-T. Chong, R.R. Hinshaw, L.A. Dolak, F.J. Schwende, B.D. Rush, G.M. Howard, L.N. Toth, K.F. Wilkinson, T.J. Kakuk, C.W. Johnson, S.L. Cole, R.M. Zaya, G.L. Zipp, P.L. Possert, R.J. Dalga, and K.R. Romines. "Structure-Based Design of Nonpeptidic HIV Protease Inhibitors: The Sulfonamide-substituted Cyclooctyl Pyranones." *J Med. Chem* **40**, 1149 (1997).
51. S. Thaisrivongs, H.I. Skulnick, S.R. Turner, J.W. Strohbach, R.A. Tommasi, P.D. Johnson, P.A. Aristoff, T. M. Judge, R.B. Gammill, J.K. Morris, K.R. Romines, R.R. Hinshaw, K.T. Chong, W.G. Tarpley, S.M. Poppe, D.E. Slade, J.C. Lynn, M.M Horng, P.K. Tomich, E.P. Seest, L.A. Dolak, W.J. Howe, G.M. Howard, F.J. Schwende, L.N. Toth, G.E. Padbury, G.J. Wilson, L. Shiou, G.L. Zipp, K.R. Wilkinson, B.D. Rush, M.J. Ruwart, K.A. Koeplinger, Z. Zhao, S. Cole, R.M. Zaya, T.J. Kakuk, M.N. Janakiraman, and K.D. Watenpaugh. "Structure-Based Design of HIV Protease Inhibitors: Sulfonamide Containing 5,6-Dihydro-4-hydroxy-2-pyrones as Non-peptidic Inhibitors." *J Med Chem* **39**, 4349 (1996).
52. W.J. Adams, P.A. Aristoff, R.K. Jensen, W. Morozowich, D.L. Romero, W.C. Schinzer, W.G. Tarpley, and R.C. Thomas. "Discovery and Development of the BHAP Non-nucleoside Reverse Transcriptase Inhibitor Delavirdine Mesylate." In *Integration of Pharmaceutical Discovery and Development: Case Studies*, ed. by R.T. Borchardt, R.M. Freidinger, T.K. Sawyer, and P.L. Smith, 285-312, Plenum Press, New York, 1998.

53. S.R. Turner, J.W. Strohbach, R. Tommasi, P.A. Aristoff, P.D. Johnson, H.I. Skulnick, L.A. Dolak, E.P. Seest, P.K. Tomich, M.J. Bohanon, M.-M. Horng, J.C. Lynn, K.-T. Chong, R.R. Hinshaw, K.D. Watenpaugh, M.N. Janakiraman, and S. Thaisrivongs. "Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class." *J Med Chem* **41**, 3467 (1998).
54. P.A. Aristoff. "Dihydropyrone Sulfonamides as a Promising New Class of HIV Protease Inhibitors." *Drugs of the Future* **23**, 995 (1998).
55. G.E. Zurenko, J.K. Gibson, D.L. Shinabarger, P.A. Aristoff, C.W. Ford, and W.G. Tarpley. "Oxazolidinones: a New Class of Antibacterials." *Current Opinion in Pharmacology* **1**, 470 (2001).
56. P.D. Johnson, P.A. Aristoff, G.E. Zurenko, R.D. Schaadt, B.H. Yagi, C.W. Ford, J. C. Hamel, D. Stapert, and J.K. Moerman. "Synthesis and Evaluation of Benzazepine Oxazolidinone Antibacterials." *Bioorganic & Med Chem Lett* **13**, 4197 (2003).
57. T.J. Poel, R.C. Thomas, W.J. Adams, P.A. Aristoff, M.R. Barbachyn, F.E. Boyer, J. Brieland, R. Brideau, J. Brodfuehrer, A.P. Brown, A.L. Choy, M. Dermeyer, M. Dority, C.W. Ford, R.C. Gadwood, D. Hanna, C. Hongliang, M.C. Huband, C. Huber, R. Kelly, J.Y. Kim, J.P. Martin, Jr., P.J. Pagano, D. Ross, L. Skerlos, M.C. Sulavik, T. Zhu, G.E. Zurenko, and J.V.N. Vara Prasad. "Antibacterial Oxazolidinones Possessing a Novel C-5 Side Chain. (5R)-trans-3-[3-Fluoro-4-(1-oxotetrahydrothiopyran-4-yl)phenyl]-2-oxooxazolidine-5-carboxylic Acid Amide (PR-00422602), a New Lead Compound." *J Med Chem* **50**, 5886 (2007).
58. P.A. Aristoff, G.A. Garcia, P.D. Kirchhoff, and H.D.H. Showalter. Rifamycins – Obstacles and Opportunities. *Tuberculosis* **90**, 94 (2010).

ABSTRACTS AND ORAL PRESENTATIONS (*Invited Lectures)

1. R.E. Ireland and P.A. Aristoff. An Approach to the Total Synthesis of Aphidicolin. 173rd American Chemical Society National Meeting, New Orleans, LA, March 22, 1977.
2. P.A. Aristoff. The Synthesis of 6a-Carbaprostaglandin I₂. Second Chemical Congress of the North American Continent, Las Vegas, NV, August 28, 1980.
3. D.R. Morton, P.A. Aristoff, and J.W. Aiken. The Total Synthesis of Carbacyclin: A Chemically Stable and Isosteric Analog of PGI₂ (Prostacyclin). Bowling Green State University, March 3, 1982.
- *4. P.A. Aristoff and A.W. Harrison. The Synthesis of Stable Prostacyclin Analogs. Middle Atlantic Regional American Chemical Society Meeting, Newark, DE, April 23, 1982.
- *5. P.A. Aristoff and A.W. Harrison. The Synthesis and SAR of Novel Stable Prostacyclin Analogs. V International Conference on Prostaglandins, Florence, Italy, May 19, 1982.
- *6. P.A. Aristoff. Synthesis and Biology of Stable Prostacyclin Analogs. Joint Meeting of the Great Lakes and Central Regions of the American Chemical Society, Kalamazoo, MI, May 24, 1984.
7. P.A. Aristoff and A.W. Harrison. Synthesis of Benzopyran Prostacyclin Analogs. 188th American Chemical Society National Meeting, Philadelphia, PA, August 30, 1984.
- *8. P.A. Aristoff, A.W. Harrison, and P.D. Johnson. Synthesis and Structure-Activity Relationships of Benzindene Prostaglandins: Novel Potent Antiulcer Agents. Kyoto Conference on Prostaglandins, Kyoto, Japan, November 26, 1984.

9. A. Robert, P.A. Aristoff, M.G. Wendling, F.A. Kimball, W.L. Miller, and R.R. Gorman. Gastrointestinal Properties of U-68,215, A Stable Prostacyclin Analog. Kyoto Conference on Prostaglandins, Kyoto, Japan, November 26, 1984.
- *10. P.A. Aristoff. Synthesis of Benzindene Prostaglandins: Novel Potent Antiulcer Agents. Teikyo University, Kanagawa, Japan, November 29, 1984.
11. A. Robert, P.A. Aristoff, M.G. Wendling, F.A. Kimball, W.L. Miller, and R.R. Gorman. Cytoprotective and Antisecretory Properties of a Non-Diarrheogenic and Non-Uterotonic Prostacyclin Analog: U-68,215. American Gastroenterological Assoc. Meeting, New York, NY, May 12-15, 1985.
- *12. P.A. Aristoff. Intramolecular Wittig Reactions in the Synthesis of Prostacyclin Analogs. Gordon Research Conference on Organic Reactions and Processes, New Hampton, NH, July 19, 1985.
- *13. P.A. Aristoff. Use of the Intramolecular Wittig Reaction in the Synthesis of Stable Prostacyclin Analogs. Hope College, Holland, MI, February 28, 1986.
14. M.A. Warpehoski, R.C. Kelly, W.C. Krueger, P.A. Aristoff, and L.H. Li. Comparison of the Antitumor Activity and DNA Binding of U-71,184 Analogs. Proceedings of the American Association of Cancer Research, Vol. 27, 1986, Abstr. 997.
- *15. P.A. Aristoff, P.D. Johnson, R.C. Kelly, and M. A. Warpehoski, Synthesis of Potent Analogs of the Novel Antitumor Agent CC-1065. Gordon Research Conference on Natural Products, New Hampton, NH, July 24, 1986.
- *16. P.A. Aristoff. Use of the Intramolecular Wittig Reaction in the Synthesis of Stable Prostacyclin Analogs. University of Texas, Austin, TX, October 24, 1986.
- *17. P.A. Aristoff. Sources for Novel Drugs for the Treatment of Cancer. BMAG/NCI Symposium on "Approaches to Antineoplastic Drug Discovery in the Pharmaceutical Industry." Phase I Meeting, Bethesda, MD, November 17, 1986.
- *18. P.A. Aristoff. Use of the Intramolecular Wittig Reaction in the Synthesis of Stable Prostacyclin Analogs. California Institute of Technology, Pasadena, CA, January 28, 1987.
- *19. P.A. Aristoff. Use of the Intramolecular Wittig Reaction in the Synthesis of Stable Prostacyclin Analogs. University of California at Los Angeles, Los Angeles, CA, January 29, 1987.
20. M.A. Mitchell, D.H. Swenson, T.L. Wallace, M.G. Williams, G.L. Petzold, P.A. Aristoff, P.D. Johnson, and L.H. Li. Antitumor and Biochemical Effects of Novel Bifunctional Agents Based on the Alkylating Subunit of CC-1065. Proceedings of the American Association of Cancer Research, Vol. 28, 1987, Abstr. 1068.
- *21. P.A. Aristoff. Recent Studies on CC-1065 and its Analogs. NSF Synthetic and Natural Products Workshop, Pingree Park, CO, July 9, 1987.
22. C.H. Lin, P.A. Aristoff, P.D. Johnson, J.P. McGrath, J.M. Timko, and A. Robert. Benzindene Prostaglandins. Synthesis of Optically Pure 15-Deoxy-U-68215 and its Enantiomer via a Modified Intramolecular Wadsworth-Emmons-Wittig Reaction. Gordon Research Conference on Natural Products, New Hampton, NH, July 21, 1987.
23. P.A. Aristoff, R.C. Kelly, P.D. Johnson, I. Gebhard, and N. Wicnienski. Recent Studies on CC-1065 and its Analogs. Gordon Research Conference on Natural Products, New Hampton, NH, July 22, 1987.

24. M.A. Mitchell, D.H. Swenson, T.L. Wallace, M.G. Williams, G.L. Petzold, P.A. Aristoff, P.D. Johnson, W.C. Krueger, M.D. Prairie, and L.H. Li. Antitumor and Biochemical Effects of Novel Bifunctional Agents Based on the Alkylating Subunit of CC-1065. Brook Lodge Conference on Drug-DNA Interactions, Augusta, MI, December 9, 1987
25. L.H. Hurley, C.-S. Lee, J. P. McGovren, M.A. Warpehoski, M.A. Mitchell, R.C. Kelly, and P.A. Aristoff. Molecular Basis for Sequence-Specific DNA Alkylation by CC-1065. Brook Lodge Conference on Drug-DNA Interactions, Augusta, MI, December 10, 1987.
26. G.L. Petzold, D.H. Swenson, P.A. Aristoff, and J.P. McGovren. Potent In Vitro Inhibition of Poly (ADP-Ribosyl) ation in Chinese Hamster Ovary (CHO) Cells by Flavone and Related Analogs, Including Flavone Acetic Acid. Proceedings of the American Association of Cancer Research, Vol. 29, 1988, Abstr. 64.
27. T.F. DeKoning, P.A. Aristoff, D.P. Houchens, and L.H. Li. Biological Evaluation of Tetraplatin and its Stereoisomers. Proceedings of the American Association of Cancer Research, Vol. 29, 1988, Abstr. 1352.
- *28. P.A. Aristoff, R.C. Kelly, M.A. Warpehoski, P.D. Johnson, I. Gebhard, N. Wicnienski, and V.S. Bradford. Recent Studies on CC-1065 and its Analogs. 7th IUPAC Conference on Organic Synthesis, Nancy, France, July 7, 1988.
- *29. P.A. Aristoff. Synthesis and Mechanism of Action of CC-1065 and Related Antitumor Agents. University of Illinois, Urbana, IL, November 3, 1988.
- *30. P.A. Aristoff. Synthesis and Mechanism of Action of CC-1065 and Related Antitumor Agents. Wayne State University, Detroit, MI, November 11, 1988.
31. F.A. Valeriote, T.H. Corbett, A. Wozniak, P.A. Aristoff, and L. Baker. An in vitro Assay for the Discovery of Anticancer Agents. Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, March 7, 1989 (Abstr. 2).
32. P.A. Aristoff, M.A. Warpehoski, M.A. Mitchell, W.C. Krueger, J.P. McGovren, and L.H. Li. Utilization of Mechanism of Action and Structure-Activity Information in the Rational Design of Highly Efficacious CC-1065 Analogs. Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, March 8, 1989 (Abstr. 62).
33. T. Corbett, J. Berthelon, P. Briet, P.A. Aristoff, L. Polin, P. LoRusso, A. Wozniak, M. Bissery, and K. Paull. Flavone Acetic Acid (FAA) (NSC-347512): Efforts to Overcome Deficiencies with Improved Analogs. Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, March 8, 1989 (Abstr. 69).
34. J.P. McGovren, R.C. Kelly, P.A. Aristoff, L.H. Li, and M.A. Mitchell. Cyclopropapyrrolloindole (CPI) Dimers: Sequence-specific DNA Binding Bis-alkylators, Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, March 10, 1989 (Abstr. 397).
35. P.D. Johnson, P.A. Aristoff, M.A. Mitchell, and M.G. Williams. Synthesis, Biological Activity, and Molecular Modeling of Novel Bifunctional Antitumor Agents Based on Two of the Alkylating Subunits of CC-1065. 197th American Chemical Society National Meeting, Dallas, TX, April 13, 1989 (Abstr. MEDI 97).
- *36. P.A. Aristoff. Synthesis and Mechanism of Action of CC-1065 and Related Antitumor Agents. Symposium on Organic Chemistry in Industry. 198th American Chemical Society National Meeting, Miami, FL, September 13, 1989. (Abstr. ORGN 175)
- *37. P. A. Aristoff. Synthesis and Mechanism of Action of CC-1065 Analogs. Gordon Research Conference on Heterocyclic Compounds, New Hampton, NH, July 11, 1990.

- *38. P. A. Aristoff. Synthesis and Mechanism of Action of CC-1065 Analogues. Second Conference of the French-American Chemical Society, Fort Myers, FL, January 11, 1991.
39. P. A. Aristoff and P. D. Johnson. Total Synthesis of Cyclopropabenzindole (CBI). Gordon Research Conference on Heterocyclic Compounds, New Hampton, NH, July 7-12, 1991.
40. I. W. Althaus, R. J. LeMay, A. J. Gonzales, M.R. Deibel, F. J. Kezdy, L. Resnick, M. E. Busso, P. A. Aristoff, F. Reusser. Mode of Action in vitro Studies with the HIV RT Inhibitor U-9843. Fourth Chemical Congress of North America, New York, NY, August 25-30, 1991, Abstr. 55.
- *41. P. A. Aristoff. Synthesis and Mechanism of Action of CC-1065 Analogues. 6th SCI-RSC Medicinal Chemistry Symposium, Cambridge, England, September 9, 1991.
42. D.L. Romero, J.R. Palmer, R.C. Thomas, M. Busso, C-K. Tan, F. Reusser, S.M. Poppe, R.A. Morge, N. Berrios-Pena, M.J., Hosley, T.J. Poel, D.C. Rohrer, P.D. Johnson, P.A. Aristoff, K.M. Downey, A.G. So, L. Resnick, W.G. Tarpley. Discovery, SAR, and Antiviral Activity of Novel BHAP HIV-1 RT Inhibitors. ICAAC, Chicago, IL, October 4, 1991, Abstr. 1338.
- *43. P.A. Aristoff. Synthesis and Structure Activity Relationships of Novel Antitumor and Antiviral Agents. University of Texas, Austin, TX, October 10, 1991.
44. D.L. Romero, R.C. Thomas, I.W. Althaus, M. Busso, P.A. Aristoff, N. Berrios-Pena, M.J. Hosley, P.D. Johnson, R.A. Morge, J.R. Palmer, T.J. Poel, S.M. Poppe, D.C. Rohrer, C.A. Willoughby, C-K. Tan, K.M. Downey, A.G. So, L. Resnick, W.G. Tarpley. Discovery, Structure-activity Relationships and Antiviral Activity of Novel Bisheteroaryl piperazine (BHAP) Human Immunodeficiency Virus-1 Reverse Transcriptase Inhibitors. Fourth Conf. Nat. Drug Disc. Groups, San Diego, CA, November 3-7, 1991.
- *45. P.A. Aristoff. Use of the Intramolecular Wadsworth-Emmons Reaction in the Synthesis of Novel Antiplatelet and Antiulcer Agents. Symposium in Honor of William Wadsworth, South Dakota State University, Brookings, SD, April 24, 1992.
46. P.D. Johnson and P.A. Aristoff. total Synthesis of (+)- and (-)-Cyclopropylbenzindole (CBI). 9th International Conference on Organic Synthesis. University of Quebec at Montreal, June 30, 1992.
47. I.W. Althaus, A.J. Gonzales, M.R. Deibel, F.J. Kezdy, D.L. Romero, P.A. Aristoff, W.G. Tarpley, F. Reusser. Kinetic Studies with the HIV-1 Reverse Transcriptase Inhibitor U-87201E. 204th American Chemical Society National Meeting, Washington, DC, August 25, 1992.
48. D.L. Romero, R.C. Thomas, R.A. Morge, T.J. Poel, M.J. Hosley, J.R. Palmer, P.A. Aristoff, P.D. Johnson, F. Reusser, I.W. Althaus, W.G. Tarpley. Discovery and Design of Potent Bisheteroaryl piperazine (BHAP) HIV-1 Reverse Transcriptase Inhibitors. 204th American Chemical Society National Meeting, Washington, DC, August 25, 1992.
49. D.L. Romero, R.C. Thomas, R.A. Morge, T.J. Poel, M.J. Hosley, J.R. Palmer, C.A. Willoughby, P.D. Johnson, D.C. Rohrer, F. Reusser, I.W. Althaus, P.A. Aristoff, W.G. Tarpley. Discovery and Design of Potent Bisheteroaryl piperazine (BHAP) HIV-1 Reverse Transcriptase Inhibitors. XII International Symposium on Medicinal Chemistry, Basel, Switzerland, September 13, 1992.
- *50. P.A. Aristoff. Synthesis of Medicinally Important Agents. Fifteenth Gulf Coast Chemistry Conference, Pensacola Beach, FL, September 18, 1992.
51. I.W. Althaus, A.J. Gonzales, M.R. Deibel, F.J. Kezdy, D.L. Romero, R.C. Thomas, J.R. Palmer, P.A. Aristoff, W.G. Tarpley, F. Reusser. Kinetic Studies with the HIV-1 Reverse Transcriptase Inhibitor U-88204E. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October 11, 1992.

- *52. P.A. Aristoff. Design and Synthesis of Anticancer and Antiviral Drugs. Rice University, Houston, TX, February 18, 1993.
- *53. P.A. Aristoff. Design and Synthesis of Anticancer and Antiviral Drugs. University of Texas, Austin, TX, February 19, 1993.
- *54. P.A. Aristoff. Discovery and Development of Therapeutic CC-1065 Analogs. Mini-Symposium on Drug/DNA Interactions. University of Washington, Seattle, WA. April 23, 1993.
- *55. P.A. Aristoff. Design and Synthesis of Anticancer-Antiviral Drugs. University of Pennsylvania, Philadelphia, PA, November 3, 1993.
- *56. P.A. Aristoff. Design of Therapeutic CC-1065 Analogs. Symposium on Pharmaceutical Design: Nucleic Acid Binding Drugs, Palo Alto, CA, January 31, 1994.
- 57. T.F. DeKoning, S.J. Couch, S.D. Weed, D.J. Waggoner, P.A. Aristoff, H.I. Skulnick, and I. Abraham. KT5720, K252a and Other Indolocarbazoles Potentiate Taxol. Proceedings of the American Association of Cancer Research, Vol 35, 1994, Abstr. 1964.
- *58. P.A. Aristoff. Design of (+)-CC-1065-Based Clinical Candidates. 24th National Medicinal Chemistry Symposium, Salt Lake City, UT, June 24, 1994.
- *59. P.A. Aristoff. Design and Synthesis of Anti-HIV Agents. University of California at Los Angeles, Los Angeles, CA, February 2, 1995.
- 60. H.I. Skulnick, P.D. Johnson, P.A. Aristoff, K.R. Romines, S. Thaisrivongs, J.W. Strohbach, S.R. Turner, W.J. Howe, P.K. Tomich, J.C. Lynn, M.M. Horng, K.D. Watenpaugh, M.N. Janakiraman, and K.T. Chong. Design, Synthesis and SAR of Novel HIV Protease Inhibitors for the Treatment of AIDS. 210th American Chemical Society National Meeting, Chicago, IL, August 20, 1995.
- *61. P.A. Aristoff. Enzyme Inhibitors for the Treatment of AIDS. AIMECS 95 - AFMC International Medicinal Chemistry Symposium, Tokyo, Japan, September 5, 1995.
- 62. P.D. Johnson, H.I. Skulnick, P.A. Aristoff, P.K. Tomich, K.T. Chong, W.J. Howe, K.D. Watenpaugh, M.N. Janakiraman, J.C. Lynn, M.M. Horng, and R.R. Hinshaw. Rational Design, Synthesis, and SAR of Arylsulfonamide Cycloalkylpyrones Exemplified by U-103017, a Non-peptidic HIV Protease Inhibitor. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, September 19, 1995.
- 63. K.T. Chong, G.L. Zipp, M.J. Ruwart, F.J. Schwende, G.E. Padbury, P.K. Tomich, K.D. Watenpaugh, W.J. Howe, P.D. Johnson, H.I. Skulnick, P.A. Aristoff, K.R. Romines, R.R. Hinshaw, and P.J. Pagano. U-103017: an Improved 4-Hydroxy-2-pyrone Inhibitor of HIV Protease. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 19, 1995.
- 64. G.L. Zipp, L. Shiou, P.L. Possert, R.J. Dalga, M.J. Ruwart, B.D. Rush, K.F. Wilkinson, F.J. Schwende, G.M. Howard, W.Z. Zhong, G.E. Padbury, P.D. Johnson, H.I. Skulnick, and P.A. Aristoff. Formulation Development and Oral Absorption of the Clinical Candidate HIV-Protease Inhibitor U-103017. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 19, 1995.
- 65. G.L. Zipp, P.L. Pastorate, R.J. Dalga, L. Shiou, K.T. Chong, P.D. Johnson, H.I. Skulnick, and P.A. Aristoff. Physical Chemical Characterization of the HIV-Protease Inhibitor Clinical Candidate U-103017. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 19, 1995.
- *66. P.A. Aristoff. Enzyme Inhibitors for the Treatment of AIDS. Current Topics in Medicinal Chemistry, Department of Chemistry, Boston University, March 1, 1996.

67. G.L. Zipp, L. Shiou, P.L. Possert, R.J. Dalga, M..J. Ruwart, B.D. Rush, K.F. Wilkinson, F.J. Schwende, W.Z. Zhong, M.G. Williams, G.E. Padbury, P.D. Johnson, H.I. Skulnick, P.A. Aristoff and S. Thaisrivongs. Identification and Development of U-103017: A Small-molecule Nonpeptidic HIV Protease Inhibitor. National ACS Meeting, Division of Medicinal Chemistry, New Orleans, LA, March 24-28, 1996.
68. S. Thaisrivongs, P.A. Aristoff, W.G. Tarpley, K.T. Chong, K.D. Watenpaugh, P.K. Tomich, L.A. Dolak, G.E. Padbury, F.J. Schwende, Z. Zhao, G.L. Zipp, T.J. Kakuk, W.J. Howe, K.R. Romines, D.L. Romero, R.A. Chrusciel, and R.B. Gammill. The Dihydropyrone: Third-generation Non-peptidic, HIV, Inhibitor Development Candidate. XI International Conference on AIDS, Vancouver, Canada, July 7-12, 1996.
69. P.K. Tomich, S. Thaisrivongs, P.A. Aristoff, K.R. Romines, W.J. Howe, K.D. Watenpaugh, K.T. Chong, F.J. Kezdy, C.S.C. Tomich, A.G. Tomasselli, and W.G. Tarpley. Application of a Fluorescent Based Particle Concentration HIV Protease Assay in the Identification of Third-Generation Nonpeptidic Dihydropyrone HIV Protease Inhibitors as Clinical Candidates. XI International Conference on AIDS, Vancouver, Canada, July 7-12, 1996.
70. H.I. Skulnick, P.D. Johnson, P.A. Aristoff, S.R. Turner, J.W. Strohbach, R.A. Tommasi, S. Thaisrivongs, L.L. Skaletzky, T.M. Judge, J.K. Morris, T.M. Castle, E.P. Seest, L.A. Dolak, M.M. Horng, J.C. Lynn, P.K. Tomich, R. R. Hinshaw, P.J. Pagano, and K.T. Chong. Design, Synthesis and SAR of Dihydropyrone Sulfonamide Non-Peptidic HIV Protease Inhibitors. XI International Conference on AIDS, Vancouver, Canada, July 7-12, 1996.
- *71. K.R. Romines and P.A. Aristoff. Asymmetric Synthesis of a New Class of Potent, Nonpeptidic HIV Protease Inhibitors. Gordon Research Conference on Heterocyclic Chemistry, New Hampton, NH, July 8, 1996.
- *72. P.A. Aristoff. Structure-Based Design of Dihydropyrone Sulfonamides as Non-peptidic HIV Protease Inhibitors. Gordon Research Conference on Medicinal Chemistry, New London, NH, August 5, 1996.
73. P.D. Johnson, H.I. Skulnick, P.A. Aristoff, D.L. Romero, R. Tommasi, J.W. Strohbach, S.R. Turner, C. Biles, R.A. Morge, T.M. Judge, J.K. Morris, R.G. Gammill, K.R. Romines, P.K. Tomich, M.M. Horng, J.C. Lynn, K.T. Chong, R.R. Hinshaw, M.N. Janakiraman, W.J. Howe, K.D. Watenpaugh, and S. Thaisrivongs. Structure-Based Design, Synthesis, and SAR of Dihydropyrone Sulfonamides as Non-Peptidic HIV Protease Inhibitors. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, LA, September 15-18, 1996.
- *74. P.A. Aristoff. Structure-based Design of Non-peptidic HIV Protease Inhibitors. 1998 Swedish Pharmaceutical Congress, Symposium on Design and Synthesis of Protease Inhibitors, Stockholm, Sweden, October 21, 1998.
- *75. P.A. Aristoff. The Oxazolidinones – Discovery and Development of New Agents for the Treatment of Bacterial Infections. University of Michigan, Ann Arbor, MI, September 27, 2000.
- *76. P.A. Aristoff. The Discovery of Oxazolidinone Antibacterial Agents. Symposium in Honor of Donald J. Cram, University of California at Los Angeles, March 28, 2002.
- *77. P.A. Aristoff. Oxazolidinone Antibacterials. Gordon Research Conference on Medicinal Chemistry, New London, NH, August 9, 2005.

78. J.V.N Vara Prasad, T.-J. Poel, R.C. Thomas, W.J. Adams, P.A. Aristoff, M.R. Barbachyn, D. P. Blakeman, F.E. Boyer, JU. Brieland, R. Brideau, J. Brodfuehrer, A.L. Choy, M. Dority, C.W. Ford, R.C. Gadwood, J.C. Hamel, M.D. Huband, C. Huber, J.-Y. Kim, J.P. Martin, Jr., P.J. Pagano, D. Ross, T. Zhu, and G.E. Zurenko. Oxazolidinones Possessing a Novel C-5 Side Chain: OF-00422602, a New Lead Compound. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, September 28, 2006.
- *79. P.A. Aristoff. Advances in the Discovery of Novel Oxazolidinone Antibacterial Agents. University of Michigan, Ann Arbor, MI, November 13, 2008.
- *80. P.A. Aristoff Some Lessons Learned in 30 Years of Drug Discovery. Trius Therapeutics, San Diego, CA, June 4, 2009.
- *81. P.A. Aristoff Discovery of Novel Oxazolidinone and QPT Antibacterial Agents. Cubist Pharmaceuticals, Lexington, MA January 11, 2010.
- *82. P.A. Aristoff New Oxazolidinone Antibacterial Agents – What Have We Learned? CHI 5th Annual Conference on Drug Discovery Chemistry, San Diego, CA. April 27, 2010.

ISSUED US PATENTS

1. P. A. Aristoff. Composition and Process (Novel Benzindene Analogs). US 4,306,075, December 15, 1981.
2. P. A. Aristoff. Composition and Process (Novel Didehydro-carbacyclin Analogs). US 4,338,457, July 6, 1982.
3. P. A. Aristoff. Composition and Process (Novel Carbacyclin Intermediates). US 4,346,041, August 24, 1982.
4. P. A. Aristoff. Methano Carbacyclin Analogs. US 4,349,689, September 14, 1982.
5. P. A. Aristoff. Benzopyran Compounds. Derivatives of Prostaglandins. US 4,401,824, August 30, 1983.
6. P. A. Aristoff. Composition and Process (9-Methylcarbacyclin Analogs). US 4,420,632, December 13, 1983.
7. P. A. Aristoff. Carbacyclin Analogs. US 4,486,598, December 4, 1984.
8. P. A. Aristoff. 9-Substituted Carbacyclin Analogs. US 4,487,961, December 11, 1984.
9. P. A. Aristoff and J. C. Sih. 9-Substituted Carbacyclin Analogs. US 4,533,749, August 6, 1985.
10. P. A. Aristoff. 9-Substituted Carbacyclin Analogs. US 4,588,823, May 13, 1986.
11. P. A. Aristoff and J. C. Sih. Novel 9-Substituted Carbacyclin Analogs. US 4,590,297, May 20, 1986.
12. P. A. Aristoff. Novel 9-Substituted Carbacyclin Analogs. US 4,628,110, December 9, 1986.
13. P. A. Aristoff. Composition and Process (Novel Carbacyclin Intermediates). US 4,525,586, June 25, 1985.
14. P. A. Aristoff. Interphenylene Carbacyclin Compound. US 4,544,764, October 1, 1985.
15. P. A. Aristoff. Interphenylene Carbacyclin Derivatives. US 4,668,814, May 26, 1987.

16. P. A. Aristoff. Interphenylene Carbacyclin Derivatives. US 4,683,330, July 28, 1987.
17. P. A. Aristoff, H. I. Skulnick, and W. Wierenga. $\Delta^{9(11)}$ -Angiostatic Steroids. US 4,975,537, December 4, 1990.
18. P. A. Aristoff. Fluorinated Flavone Acetic Acid. US 5,238,954, August 23, 1993.
19. R. C. Kelly, D. G. Martin, and P. A. Aristoff. CC-1065 Analogs. US 5,332,837, July 26, 1994.
20. J. R. Palmer, P. A. Aristoff, and D. L. Romero. Anti-AIDS Piperazines. US 5,489,593, February 6, 1996.
21. R.C. Kelly and P.A. Aristoff. CC-1065 Analogs Having Two CPI Subunits. US Patent 5,541,339, July 30, 1996.
22. J.R. Palmer, D.L. Romero, P.A. Aristoff, R.C. Thomas, and H.W. Smith. Diaromatic Substituted Compounds as Anti-HIV Agents. US 5,563,142, October 8, 1996.
23. P.K. Tomich, M.J. Bohanon, S.R. Turner, J.W. Strohbach, S. Thaisrivongs, R.C. Thomas, K.R. Romines, C.-P. Yang, P.A. Aristoff, H.I. Skulnick, P.D. Johnson, R.B. Gammill, Q. Zhang, G.L. Bundy, D.J. Anderson, and L.S. Banitt. 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl(b)pyran-2-ones useful to treat retroviral infections. US 5,686,486, November 11, 1997.
24. R.C. Kelly, M.A. Mitchell, and P.A. Aristoff. CC-1065 Analogs. US 5,739,350, April 14, 1998.
25. K.R. Romines, G.L. Bundy, T.M. Schwartz, R.A. Tommasi, J.W. Strohbach, S. R. Turner, S. Thaisrivongs, P.A. Aristoff, P.D. Johnson, H. I. Skulnick, L.L. Skaletzky, D.J. Anderson, J. Morris, R.G. Gammill, and G.P. Luke. Pyranone compounds useful to treat retroviral infections. US 5,852,195, December 22, 1998.
26. J.W. Wilks, T.F. DeKoning, and P.A. Aristoff. Steroids which Inhibit Angiogenesis. US 5,972,922, October 26, 1999.
27. R.A. Chrusciel, L.L. Maggiora, S. Thaisrivongs, J.M. Tustin, C.W. Smith, R.A. Tommasi, P.A. Aristoff, H.I. Skulnick, W.J. Howe, and G.L. Bundy. Substituted tetronic acids useful for treating HIV and other retroviruses. US 5,977,169, November 2, 1999.
28. R.A. Chrusciel, L.L. Maggiora, S. Thaisrivongs, J.M. Tustin, C.W. Smith, R.A. Tommasi, P.A. Aristoff, H.I. Skulnick, and W.J. Howe. Substituted tetronic acids useful for treating HIV and other retroviruses. US 6,060,600, May 9, 2000.
29. K.R. Romines, G.L. Bundy, T.M. Schwartz, R.A. Tommasi, J.W. Strohbach, S.R. Turner, S. Thaisrivongs, P.A. Aristoff, P.D. Johnson, H.I. Skulnick, L.L. Skaletzky, D.J. Anderson, J. Morris, R.B. Gammill, and G.P. Luke. Compounds useful to treat retroviral infections. US 6,169,181, January 2, 2001.
30. P.D. Johnson, P.A. Aristoff, T. Poel, and L.M. Thomasco. Oxazolidinones having benzannulated 6- or 7-membered heterocycles. US 6,972,286, December 6, 2005.

ASSOCIATIONS

American Chemical Society, American Association for the Advancement of Science, American Association for Cancer Research, American Society for Microbiology